April 3, 2024 by admin aurigene Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers
April 3, 2024 by admin aurigene Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor
April 3, 2024 by admin aurigene Discovery of AUR-112, a novel MALT1 protease inhibitor for the treatment of B cell lymphomas
April 3, 2024 by admin aurigene Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers
April 3, 2024 by admin aurigene Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
September 15, 2023 by admin aurigene Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion, and Therapeutic Resistance Aurigene’s AUR109_DDR1-SIK2-Wnt-Catenin inhibitor for PFI2023 v2
August 8, 2023 by admin aurigene Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
July 31, 2023 by admin aurigene A phase 1, open label, dose escalation, First-in-Human (FIH) study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR 103 in patients with relapsed advanced malignancies (BHARAT-1)
May 22, 2023 by admin aurigene Generation of profound anti-tumor immunity by AUR109, a spectrum-selective kinase inhibitor, either as a single agent or in combination with immune checkpoint inhibitors 20230418_AUR109_AACR2023_4030
May 22, 2023 by admin aurigene ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
